# GeoVax Labs, Inc.: financial statements, quarterly

GOVX · Nasdaq · CIK 832489 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/govx.md) · [Financials](/companies/govx/financials.md) · [Filings](/companies/govx/filings.md) · [Insiders](/companies/govx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/govx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0001437749-24-034530.md) | [0.0 d](/filings/0001437749-25-009614.md) | [0.0](/filings/0001437749-25-014083.md) | [301](/filings/0001437749-25-023651.md) | [2,789](/filings/0001437749-25-034811.md) | [864 d](/filings/0001437749-26-012377.md) | [1,637](/filings/0001437749-26-017048.md) | [852](/filings/0001437749-26-024523.md) | [0.0](/filings/0001437749-25-034811.md) | [0.0 d](/filings/0001437749-26-012377.md) | [0.0](/filings/0001437749-26-017048.md) | [0.0](/filings/0001437749-26-024523.md) |
| Research and development | $k | [6,948](/filings/0001437749-24-034530.md) | [6,234 d](/filings/0001437749-25-009614.md) | [4,426](/filings/0001437749-25-014083.md) | [4,277](/filings/0001437749-25-023651.md) | [7,403](/filings/0001437749-25-034811.md) | [7,608 d](/filings/0001437749-26-012377.md) | [5,355](/filings/0001437749-26-017048.md) | [4,729](/filings/0001437749-26-024523.md) | [5,044](/filings/0001437749-25-034811.md) | [2,994 d](/filings/0001437749-26-012377.md) | [3,903](/filings/0001437749-26-017048.md) | [3,111](/filings/0001437749-26-024523.md) |
| Operating income | $k | [(8,600)](/filings/0001437749-24-034530.md) | [(7,694) d](/filings/0001437749-25-009614.md) | [(5,883)](/filings/0001437749-25-014083.md) | [(5,062)](/filings/0001437749-25-023651.md) | [(5,855)](/filings/0001437749-25-034811.md) | [(8,344) d](/filings/0001437749-26-012377.md) | [(5,405)](/filings/0001437749-26-017048.md) | [(5,419)](/filings/0001437749-26-024523.md) | [(6,373)](/filings/0001437749-25-034811.md) | [(4,442) d](/filings/0001437749-26-012377.md) | [(5,273)](/filings/0001437749-26-017048.md) | [(4,442)](/filings/0001437749-26-024523.md) |
| Interest expense | $k | [0.0](/filings/0001437749-24-034530.md) | [0.0 d](/filings/0001437749-25-009614.md) | not reported | [7.3](/filings/0001437749-25-023651.md) | [14.1](/filings/0001437749-25-034811.md) | [0.0 d](/filings/0001437749-26-012377.md) | not reported | [0.0](/filings/0001437749-25-023651.md) | [0.0](/filings/0001437749-25-034811.md) | [0.0 d](/filings/0001437749-26-012377.md) | not reported | not reported |
| Income tax | $k | [0.0 d](/filings/0001437749-24-034530.md) | not reported | [0.0](/filings/0001437749-25-014083.md) | [0.0 d](/filings/0001437749-25-023651.md) | [0.0 d](/filings/0001437749-25-034811.md) | not reported | [0.0](/filings/0001437749-25-014083.md) | [0.0](/filings/0001437749-26-024523.md) | [0.0 d](/filings/0001437749-25-034811.md) | [0.0 d](/filings/0001437749-26-017048.md) | [0.0](/filings/0001437749-26-017048.md) | [0.0](/filings/0001437749-26-024523.md) |
| Net income | $k | [(8,409)](/filings/0001437749-24-034530.md) | [(7,592) d](/filings/0001437749-25-009614.md) | [(5,850)](/filings/0001437749-25-034811.md) | [(5,064)](/filings/0001437749-25-034811.md) | [(5,815)](/filings/0001437749-25-034811.md) | [(8,263) d](/filings/0001437749-26-012377.md) | [(5,358)](/filings/0001437749-26-024523.md) | [(5,370)](/filings/0001437749-26-024523.md) | [(6,319)](/filings/0001437749-25-034811.md) | [(4,418) d](/filings/0001437749-26-012377.md) | [(5,262)](/filings/0001437749-26-024523.md) | [(4,427)](/filings/0001437749-26-024523.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(4.75)](/filings/0001437749-24-034530.md) | not reported | [(2.47)](/filings/0001437749-25-014083.md) | [(1.99)](/filings/0001437749-25-023651.md) | [(0.91)](/filings/0001437749-25-034811.md) | not reported | [(11.20)](/filings/0001437749-26-017048.md) | [(8.74)](/filings/0001437749-26-024523.md) | [(0.31)](/filings/0001437749-25-034811.md) | not reported | [(2.62)](/filings/0001437749-26-017048.md) | [(0.97)](/filings/0001437749-26-024523.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [12.7](/filings/0001437749-23-030926.md) | [6.5](/filings/0001437749-25-009614.md) | [0.8](/filings/0001437749-24-016605.md) | [1.6](/filings/0001437749-24-024867.md) | [8.6](/filings/0001437749-24-034530.md) | [5.5](/filings/0001437749-26-012377.md) | [7.4](/filings/0001437749-25-014083.md) | [3.1](/filings/0001437749-25-023651.md) | [5.0](/filings/0001437749-25-034811.md) | [3.1](/filings/0001437749-26-024523.md) | [1.3](/filings/0001437749-26-017048.md) | [3.1](/filings/0001437749-26-024523.md) |
| Current assets | $m | [14.8](/filings/0001437749-23-030926.md) | [7.9](/filings/0001437749-25-009614.md) | [2.9](/filings/0001437749-24-016605.md) | [3.8](/filings/0001437749-24-024867.md) | [10.9](/filings/0001437749-24-034530.md) | [7.9](/filings/0001437749-26-012377.md) | [10.6](/filings/0001437749-25-014083.md) | [5.1](/filings/0001437749-25-023651.md) | [6.5](/filings/0001437749-25-034811.md) | [5.3](/filings/0001437749-26-024523.md) | [2.4](/filings/0001437749-26-017048.md) | [4.2](/filings/0001437749-26-024523.md) |
| Total assets | $m | [16.2](/filings/0001437749-23-030926.md) | [9.3](/filings/0001437749-25-009614.md) | [3.4](/filings/0001437749-24-016605.md) | [4.1](/filings/0001437749-24-024867.md) | [11.1](/filings/0001437749-24-034530.md) | [8.2](/filings/0001437749-26-012377.md) | [10.8](/filings/0001437749-25-014083.md) | [5.4](/filings/0001437749-25-023651.md) | [6.7](/filings/0001437749-25-034811.md) | [6.3](/filings/0001437749-26-024523.md) | [3.0](/filings/0001437749-26-017048.md) | [4.6](/filings/0001437749-26-024523.md) |
| Current liabilities | $m | [7.1](/filings/0001437749-23-030926.md) | [3.5](/filings/0001437749-25-009614.md) | [3.3](/filings/0001437749-24-016605.md) | [6.4](/filings/0001437749-24-024867.md) | [2.6](/filings/0001437749-24-034530.md) | [3.1](/filings/0001437749-26-012377.md) | [2.9](/filings/0001437749-25-014083.md) | [2.5](/filings/0001437749-25-023651.md) | [1.8](/filings/0001437749-25-034811.md) | [1.9](/filings/0001437749-26-024523.md) | [2.3](/filings/0001437749-26-017048.md) | [2.7](/filings/0001437749-26-024523.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [3.1](/filings/0001437749-26-012377.md) | not reported | not reported | not reported | [2.5](/filings/0001437749-26-024523.md) | [2.5](/filings/0001437749-26-017048.md) | [2.9](/filings/0001437749-26-024523.md) |
| Shareholders' equity | $m | [9.1](/filings/0001437749-24-034530.md) | [5.8](/filings/0001437749-26-012377.md) | [0.1](/filings/0001437749-25-034811.md) | [(2.3)](/filings/0001437749-25-034811.md) | [8.5](/filings/0001437749-25-034811.md) | [5.0](/filings/0001437749-26-024523.md) | [7.9](/filings/0001437749-26-024523.md) | [2.8](/filings/0001437749-26-024523.md) | [4.9](/filings/0001437749-25-034811.md) | [3.8](/filings/0001437749-26-024523.md) | [0.5](/filings/0001437749-26-024523.md) | [1.8](/filings/0001437749-26-024523.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.1) d](/filings/0001437749-24-034530.md) | [(10.3) d](/filings/0001437749-25-009614.md) | [(5.7)](/filings/0001437749-25-014083.md) | [(1.9) d](/filings/0001437749-25-023651.md) | [(9.3) d](/filings/0001437749-25-034811.md) | [(7.8) d](/filings/0001437749-26-012377.md) | [(6.0)](/filings/0001437749-26-017048.md) | [(4.3) d](/filings/0001437749-26-024523.md) | [(6.2) d](/filings/0001437749-25-034811.md) | [(5.0) d](/filings/0001437749-26-012377.md) | [(3.5)](/filings/0001437749-26-017048.md) | [(3.7) d](/filings/0001437749-26-024523.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001437749-24-034530.md) | [0.0 d](/filings/0001437749-25-009614.md) | [0.0](/filings/0001437749-25-014083.md) | [0.0 d](/filings/0001437749-25-023651.md) | [0.0 d](/filings/0001437749-25-034811.md) | [0.0 d](/filings/0001437749-26-012377.md) | [0.0](/filings/0001437749-26-017048.md) | [0.0 d](/filings/0001437749-26-024523.md) | [0.0 d](/filings/0001437749-25-034811.md) | [0.0 d](/filings/0001437749-26-012377.md) | [0.0](/filings/0001437749-26-017048.md) | [0.0 d](/filings/0001437749-26-024523.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Shares outstanding: 7,369,243 at 2026-07-27, from the cover of the [10-Q filed 2026-07-27](/filings/0001437749-26-024523.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.